Home  »  Markets   »  Royalty Pharma plc (RPRX) Review – Making Sm...

Royalty Pharma plc (RPRX) Review – Making Smarter Decisions

199 institutions hold shares in Royalty Pharma plc (RPRX), with 67.91M shares held by insiders accounting for 17.50% while institutional investors hold 53.84% of the company’s shares. The shares outstanding are 398.52M, and float is at 101.25M with Short Float at 13.77%. Institutions hold 44.42% of the Float.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Adage Capital Partners GP L.L.C. with over 38.71 million shares valued at $1.94 billion. The investor’s holdings represent 9.97% of the RPRX Shares outstanding. As of Dec 30, 2020, the second largest holder is FMR, LLC with 24.94 million shares valued at $1.25 billion to account for 6.43% of the shares outstanding. The other top investors are Morgan Stanley which holds 23.8 million shares representing 6.13% and valued at over $1.19 billion, while Vantage Consulting Group, Inc holds 5.53% of the shares totaling 21.48 million with a market value of $1.07 billion.

Royalty Pharma plc (NASDAQ: RPRX) is -14.57% lower on its value in year-to-date trading and has touched a low of $34.80 and a high of $56.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RPRX stock was last observed hovering at around $42.83 in the last trading session, with the day’s loss setting it -0.07% off its average median price target of $51.50 for the next 12 months. It is also 23.64% off the consensus price target high of $56.00 offered by 8 analysts, but current levels are 9.02% higher than the price target low of $47.00 for the same period.

Currently trading at $42.76, the stock is -6.31% and -9.94% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.45 million and changing -0.16% at the moment leaves the stock -3.94% off its SMA200. RPRX registered a gain of 6.29% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $46.29 and a 200-day simple moving average (SMA200) of $44.45.

The stock witnessed a -9.06% loss in the last 1 month and extending the period to 3 months gives it a -12.03%, and is -8.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.42% over the week and 4.08% over the month.

Royalty Pharma plc (RPRX) has around 51 employees, a market worth around $26.00B and $2.12B in sales. Current P/E ratio is 32.67 and Fwd P/E is 14.34. Profit margin for the company is 23.30%. Distance from 52-week low is 22.87% and -24.32% from its 52-week high. The company has generated returns on investments over the last 12 months (14.70%).

Royalty Pharma plc (RPRX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Royalty Pharma plc (RPRX) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.40, where 4 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Royalty Pharma plc quarterly earnings per share for the current quarter are estimated at $0.67 with sales reaching $508.63M over the same period.The EPS is expected to shrink by -66.60% this year, but quarterly earnings will post -7.60% year-over-year.

Royalty Pharma plc (RPRX) Insider Activity

The most recent transaction is an insider sale by Lloyd George W., the company’s EVP, Investments & GC. SEC filings show that Lloyd George W. sold 54,729 shares of the company’s common stock on Mar 22 at a price of $46.32 per share for a total of $2.54 million. Following the sale, the insider now owns 64013.0 shares.

Royalty Pharma plc disclosed in a document filed with the SEC on Mar 22 that Reddoch James F. (EVP, Research & Investments) sold a total of 43,927 shares of the company’s common stock. The trade occurred on Mar 22 and was made at $46.32 per share for $2.03 million. Following the transaction, the insider now directly holds 0.26 million shares of the RPRX stock.

Still, SEC filings show that on Mar 03, Coyne Terrance P. (EVP & CFO) disposed off 100,000 shares at an average price of $44.78 for $4.48 million. The insider now directly holds 200,000 shares of Royalty Pharma plc (RPRX).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam